TruSpine Technologies Plc

Transaction in Own Shares • Mar 21, 2024

National Storage Mechanism | Additional information

RNS Number : 6946H

TruSpine Technologies PLC

21 March 2024

21 March 2024

TruSpine Technologies plc

("TruSpine" or the "Company")

Director Dealing

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that it received notification on 20 March 2024 that Geoff Miller, Chairman of the Company, made the following purchase of ordinary shares in the capital of the Company on 20 March 2024. Further details are set out in the Notification of Dealing Form below.

Director	Purchase price (Aggregated)	Ordinary shares purchased	Resultant interest in ordinary shares	Resultant percentage of issued ordinary shares
Geoff Miller	0.75 pence	500,000	10,111,828	7.24%

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

TruSpine Technologies Plc	Tel: +44 (0)20 7118 0852
Laurence Strauss, Chief Executive Officer
Cairn Financial Advisers LLP (AQSE Corporate Adviser)	Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Peterhouse Capital Limited (Broker & Financial Adviser)	Tel: +44 (0)20 7469 0930
Lucy Williams / Duncan Vasey
Novus Communications (PR and IR)	Tel: +44 (0)207 448 9839
Alan Green / Jacqueline Briscoe	[email protected]

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Geoffrey Richard Miller
2	Reason for notification
a.	Position/Status	Chairman
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	TruSpine Technologies Plc
b.	LEI	213800HNZX9B1QZPB225
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 0.01 pence each ISIN: GB00BMZCKL55
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
0.75 pence	500,000
d.	Aggregated information -       Volume -       Price	N/A
e.	Date of the transaction	20 March 2024
f.	Place of the transaction	Aquis Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXDBGDXIUDDGSG